SCHEMBL1623070

SCHEMBL1623070

N#CC1CCCCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17260756 0.98 KMT2A (0.46)
SCHEMBL4418711 0.98 KMT2A (0.46)
SCHEMBL477760 0.93
SCHEMBL1396024 0.82
Thiophene SCHEMBL29286254 0.78 NPSR1 (0.32)
SCHEMBL15751039 0.76
SCHEMBL12073693 0.71
SCHEMBL28635175 0.71
SCHEMBL6039377 0.70
SCHEMBL28236101 0.70 DPP4 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3143055-A2 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP Bridgestone Corporation (JP) 2017-03-22 EP claimed
WO-2015175280-A2 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 WO claimed
EP-4676923-A1 BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS Cancer Research Technology Limited (GB) 2026-01-14 EP disclosed
US-20260001886-A1 ENPP1 INHIBITORS I RE VENTURES I LLC (US) 2026-01-01 US disclosed
WO-2025233863-A1 ENPP1 INHIBITORS RE VENTURES I, LLC (US) 2025-11-13 WO disclosed
US-12281101-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2025-04-22 US disclosed
WO-2024184550-A1 BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-09-12 WO disclosed
US-12006321-B2 Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists Sanford Burnham Prebys Medical Discovery Institute (US) 2024-06-11 US disclosed
EP-3760625-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2024-03-27 EP disclosed
CN-114149409-B (hetero) aryl amide compound with protein kinase inhibition activity 中国药科大学 2024-03-22 CN disclosed
US-11834407-B2 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-12-05 US disclosed
US-6130228-A Polycyclic compounds UNIVERSITY OF STRATHCLYDE (GB) 2000-10-10 US disclosed
EP-0877735-A1 POLYCYCLIC COMPOUNDS University of Strathclyde (GB) 1998-11-18 EP disclosed
EP-0632010-B1 Process for the preparation of diesters of alpha, omega dicarboxylic acids BASF AG (DE) 1997-09-17 EP disclosed
WO-1997019929-A1 POLYCYCLIC COMPOUNDS THE UNIVERSITY OF STRATHCLYDE (GB) 1997-06-05 WO disclosed
US-5453535-A Preparation of α,ω-dicarboxylic acid diesters BASF AKTIENGESELLSCHAFT (DE) 1995-09-26 US disclosed
US-5449686-A Compounds useful for treating allergic or inflammatory diseases SMITHKLINE BEECHAM CORPORATION (US) 1995-09-12 US disclosed
EP-0632010-A1 Process for the preparation of diesters of alpha, omega dicarboxylic acids BASF Aktiengesellschaft (DE) 1995-01-04 EP disclosed
US-4108628-A Cycloalkanopyrazole herbicides mixtures E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-08-22 US disclosed
US-4059434-A Cycloalkanapyrazole herbicides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-11-22 US disclosed